Phase 2 Study of Intermittent Oral Dosing of CM082 in Patients With Wet-AMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Vorolanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors AnewPharma
- 17 Sep 2019 Planned primary completion date changed from 8 Aug 2019 to 8 Aug 2020.
- 10 Jan 2019 Status changed from not yet recruiting to recruiting.
- 25 Oct 2018 New trial record